Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Follow-on Biologics Go Back To The Future: Senate Cmte. Endorses 12 Years of Brand Exclusivity

This article was originally published in The Pink Sheet Daily

Executive Summary

Hatch/Enzi/Hagan amendment retains the number from last year's bill, but a fight on floor seems possible.
Advertisement

Related Content

Follow-On Biologics: Defeat For Waxman, Win For Health Reform
Follow-On Biologics: Defeat For Waxman, Win For Health Reform
Follow-On Biologics: Defeat For Waxman, Win For Health Reform
Follow-On Biologics: Defeat For Waxman, Win For Health Reform
Eshoo Amendment Would Allow Substitution Of Biosimilars Without Health Care Provider Okay
And Then There Were 12: Follow-on Biologics Picture Coming Into Focus
Follow-on Biologics: Rep. Eshoo Revising Her Bill To Be Closer To Senate Provision
Sen. Brown Vows Floor Fight On Follow-on Biologics
Follow-on Biologics Vote Time: Eshoo Plans Challenge Of Waxman At House Mark-up
Follow-on Biologics Vote Time: Eshoo Plans Challenge Of Waxman At House Mark-up

Topics

Advertisement
UsernamePublicRestriction

Register

PS069686

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel